Hypertonic Saline in Bronchiolitis and Type I Error: A Trial Sequential Analysis.

Area of Science:

• Pediatrics
• Respiratory Medicine
• Evidence-Based Medicine

Background:

• Meta-analyses on nebulized hypertonic saline (HS) for acute viral bronchiolitis show conflicting results.
• Conventional meta-analyses may be susceptible to errors, leading to uncertain conclusions.
• Trial sequential analysis (TSA) is a method to assess the robustness of meta-analysis findings by determining required information size.

Purpose of the Study:

• To utilize TSA to evaluate the sufficiency of existing literature on the efficacy of HS in treating acute viral bronchiolitis.
• To determine if current evidence supports a definitive conclusion on the benefits of HS for bronchiolitis patients.

Main Methods:

• A cohort of studies from previous conventional meta-analyses was used.
• Included studies compared HS with normal saline or supportive care in children with bronchiolitis.
• TSA was applied to assess the required information size and statistical significance for outcomes like length of stay and hospitalization risk.

Main Results:

• Conventional meta-analysis suggested a statistically significant benefit of HS in reducing length of stay (LOS) (-0.41 days).
• However, TSA indicated that the information size was insufficient (2665 patients required), suggesting premature conclusions.
• For hospitalization risk, conventional meta-analysis showed a reduction (RR=0.86), but TSA also found the information size inadequate (4770 patients required).

Conclusions:

• TSA suggests that the apparent benefits of HS for bronchiolitis may be due to type I error (false positives).
• The current evidence base may not be sufficient to confirm the effectiveness of HS in reducing LOS or hospitalizations.
• Further high-quality studies are needed to definitively establish the role of HS in managing acute viral bronchiolitis.